Skip to main content
OpenTrials
Completed

NCT Number: NCT00852371

Intermittent Preventive Treatment of Malaria in Schoolchildren

This will be a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety and tolerability of antimalarial regimens in healthy schoolchildren. The primary objective of the study is to compare the efficacy of different combination antimalarial regimens, including amodiaquine + sulfadoxine-pyrimethamine (AQ+SP), dihydroartemisinin-piperaquine (DP), and placebo, to SP for intermittent preventive treatment (IPT) in schoolchildren, as measured by risk of parasitaemia (unadjusted by genotyping) after 42 days of follow-up. This will assess both the efficacy for treatment of asymptomatic infections and the efficacy for prevention of new infections.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

The study will be carried out among children aged ≥ 8 to < 14 years (boys) and ≥ 8 to < 12 years (girls) attending primary schools in Tororo district. Schools will be selected using convenience sampling with the assistance of the district and the education sector. The target population includes children attending primary schools in Uganda. The accessible population includes the children attending the participating primary schools in classes 3-7 in Tororo district. Children who meet the selection criteria for participation in the study will be randomized to treatment with one of the four study regimens and will be followed for 42 days. Repeat evaluations will be performed on days 1, 2, 3, 7, 14, 28, and 42 (and any unscheduled day that a student is ill) and will include assessment for the occurrence of adverse events. Treatment efficacy outcomes will be assessed using revised WHO outcome classification criteria. Acceptability of treatment regimens will be assessed using a questionnaire administered to participating students on day 7. The primary outcome measure is risk of parasitaemia (unadjusted by genotyping) after 42 days of follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 8 to < 14 years (boys), ≥ 8 to < 12 years (girls)
  • Student enrolled at participating school in classes 3-7
  • Provision of informed consent from parent or guardian
  • Provision of assent by student

Exclusion criteria

  • Known allergy or history of adverse reaction to study medications
  • Onset of menstruation (girls)
  • Fever (≥ 37.5°C axillary) or history of fever in the previous 24 hours
  • Evidence of severe malaria or danger signs
  • Haemoglobin < 7.0 gm/dL
  • Parasite density > 10,000/ul

Treatment and study plan

Sulfadoxine-Pyrimethamine

Drug

25 mg/kg po once on day 0

Other names: Fansidar, Roche

amodiaquine + sulfadoxine-pyrimethamine

Drug

Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0

Other names: Camoquin, Pfizer, Fansidar, Roche

Dihydroartemisinin-Piperaquine

Drug

2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)

Other names: Duocotexcin, Holley Cotec Pharmaceuticals

Placebo

Other

dosed as for amodiaquine (10mg/kg po daily on days 1, 2)

Other names: No active ingredient

Primary outcomes

  1. Risk of Parasitaemia (Unadjusted by Genotyping)

    Time frame: after 42 days of follow-up

    Proportion of participants whose thick blood smears that are positive for asexual parasites

Secondary outcomes

  1. Risk of Recrudescence (Adjusted by Genotyping) in Participants Who Were Parasitaemic at Enrollment

    Time frame: after 42 days of follow-up

    Proportion of participants whose thick blood smears that are positive with the same asexual parasites at baseline and on the day of failure at genotyping

  2. Risk of New Infection (Adjusted by Genotyping) in All Participants

    Time frame: after 42 days of follow-up

    Proportion of participants whose thick blood smears that are positive for new asexual parasites on day of failure at genotyping

  3. Risk of Clinical Failure Due to Recrudescence (Adjusted by Genotyping) in Children Who Were Parasitaemic at Enrollment

    Time frame: Over 42 days of follow-up

    Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up

  4. Mean Change in Haemoglobin

    Time frame: Between day 0 to day 42

    Haemoglobin measured in g/dL; Mean change in haemoglobin calculated as the difference in mean haemoglobin (g/dL) on Day 42 - Day 0, in children treated with the different antimalarial regimens

  5. Risk of Serious Adverse Events

    Time frame: over 42 days of follow-up

    Any untoward medical occurrence in a participant taking study medication after 14 and 42 days of follow up leading to death, disability, hospitalization or extended hospitalization

  6. Acceptability of IPT Regimens

    Time frame: on day 7

    Perceived willingness to take study medication as routine preventive treatment

  7. Risk of Clinical Failure Due to Recrudescence (Adjusted by Genotyping) in Children Who Were Parasitaemic at Enrollment

    Time frame: after 42 days of follow-up

    Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up

Sponsors and collaborators

Lead sponsor

London School of Hygiene and Tropical Medicine

Other

Collaborators

  • Ministry of Health, Uganda
  • Uganda Malaria Surveillance Project

Registry information

Official study title

IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Feb 27, 2009
Registry last updated
Mar 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.